<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00176124</url>
  </required_header>
  <id_info>
    <org_study_id>UniKlinMa-TF-2001-1</org_study_id>
    <secondary_id>ISRCTN 99578441</secondary_id>
    <nct_id>NCT00176124</nct_id>
  </id_info>
  <brief_title>Leukocyte Depletion of Autologous Whole Blood</brief_title>
  <acronym>LDAWB-2001</acronym>
  <official_title>Leukocyte Depletion of Autologous Whole Blood: Impact on Perioperative Infection Rate and Length of Hospital Stay for Hip Arthroplasty Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leukocyte depletion of autologous whole blood prior to storage does not reduce infection rate&#xD;
      (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay but&#xD;
      may increase retransfusion perioperatively during hip arthroplasty and allogenic transfusion&#xD;
      rate&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Informed Consent Form:&#xD;
&#xD;
      Prior to the first blood donation, in- and exclusion criteria should be tested. Then the&#xD;
      patient is to inform by the investigator about the studies aim and participation conditions&#xD;
      such as methods, risks, assurance, data security, etc. The patient and the investigator&#xD;
      should sign the informed consent form.&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
      If all inclusion criteria are well given and exclusion criteria are absent, the patient could&#xD;
      be enrolled and randomized, prior to the first PAD. Enrollment is parallel in all centers&#xD;
      until the final number of 1088 is reached. Breaking the seal of the provided randomization&#xD;
      envelope with computerized randomization codes completes randomization. Time and date should&#xD;
      be noted.&#xD;
&#xD;
      Blinding:&#xD;
&#xD;
      Randomization is done by the investigator, which should manage the blood donation. The blood&#xD;
      bags after inline leukocyte depletion prior to storage do not look different from not&#xD;
      depleted bags and are labeled only with the patient's identity and the subjects ID. The&#xD;
      allocation to the group is to keep secret from patient, surgeon and anesthesiologist.&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      A PAD:&#xD;
&#xD;
      Group 1 Preoperative Donation of multiple units ( more than 2) 450 mL autologous whole blood&#xD;
      and storage without leukocyte depletion Usual criteria and methods of PAD are used according&#xD;
      to regional guidelines of blood donations in the respective center.&#xD;
&#xD;
      Group 2 Preoperative Donation of multiple units (more than 2) 450 mL autologous whole blood&#xD;
      and storage following leukocyte depletion 2 to 4 hours after whole blood donations, the whole&#xD;
      blood bags should be in-line filtered by the use of leukocyte filtration sets (provided by&#xD;
      Pall Medical Company). Storage as in group 1 at 4 degree C in a blood fridge.&#xD;
&#xD;
      A as proposal, the Mannheim concept reveals a 95 percent security in avoidance of allogenic&#xD;
      transfusions for a blood loss of 20-25 ml per kg body weight: Intended are 3 donations in&#xD;
      weekly intervals. If Hb plasma con-tent decreases below 11 g/dL, the donation will be&#xD;
      postponed to the fol-lowing week. Surgery is at the fifth week after the first donation.&#xD;
&#xD;
      B Anesthesia and Surgery:&#xD;
&#xD;
      As usual in the center, and without a difference between the two groups anesthesia and&#xD;
      surgery should be performed under following aspects:&#xD;
&#xD;
        -  At hospital admission, the actual history should be taken, study measures (Appendix 1)&#xD;
           and screening laboratory should be withdrawn prior to anesthesia to compute the&#xD;
           infection risk assessment of the respective patient 13.&#xD;
&#xD;
        -  Both general and regional (spinal or epidural anesthesia) can be performed&#xD;
&#xD;
        -  Normothermia of the patients is essential to the infection rate, hypothermia increases&#xD;
           the infection rate by every degree! The intra- and postoperative core temperature range&#xD;
           will be requested.&#xD;
&#xD;
        -  Circulatory monitoring should be performed according to the centers conventions.&#xD;
           Monitoring with a 5 channel ECG is suggested. Normovolemia is essential because&#xD;
           hypovolemia is related to increased infection rate by hypoperfusion of the wound14-16.&#xD;
           Therefore, a central venous catheter is useful but not obligatory, but urine output is&#xD;
           required since it is a more sensitive volume indicator in absence of significant heart&#xD;
           and renal failure (and common practice in hip surgery). An arterial line is not&#xD;
           obligatory required.&#xD;
&#xD;
        -  Bladder catheter (Urine production more than 1ml/kg KG/h)&#xD;
&#xD;
        -  Cell Savers and hemodilution (iso- or hypervolemic) are not accepted.&#xD;
&#xD;
        -  Blood loss is to calculate carefully by subtracting rinsing from suction volumes and&#xD;
           weighing sponges and drapes intraoperatively. Postoperatively the drainage volumes are&#xD;
           sufficient if not massive expansion of thighs or hip occurs ( however, this should be&#xD;
           noted as AE).&#xD;
&#xD;
        -  In the case that allogenic transfusion is required additionally, this should be&#xD;
           leukodepleted.&#xD;
&#xD;
        -  Intra- und postoperative transfusion trigger are similar for autologous and allogenic&#xD;
           transfusion:&#xD;
&#xD;
        -  Hb greater than 8,5 plus minus 0,5&#xD;
&#xD;
        -  HF over 100 plusminus 10 /min or 35% above base line&#xD;
&#xD;
        -  MAP below 60 plusminus 5 mmHg or 35% below base line&#xD;
&#xD;
        -  Stenocardia, chest pain&#xD;
&#xD;
        -  ST-segment changes greater than 0,2 ms&#xD;
&#xD;
      Further documentation of&#xD;
&#xD;
        -  ASA&#xD;
&#xD;
        -  sex&#xD;
&#xD;
        -  weight&#xD;
&#xD;
        -  height&#xD;
&#xD;
        -  Anesthesia duration&#xD;
&#xD;
        -  OP-duration&#xD;
&#xD;
        -  Blood loss(intra- and postoperatively)&#xD;
&#xD;
        -  Lowest diastole. RR intraoperatively as well as postoperatively POD 0&#xD;
&#xD;
        -  Time of transfusions&#xD;
&#xD;
        -  Time of urine catheter withdrawal Infection-Monitoring&#xD;
&#xD;
      Parameter:&#xD;
&#xD;
      • Skin inspection&#xD;
&#xD;
      Criteria of wound infection:&#xD;
&#xD;
        -  secretion clear or pus,&#xD;
&#xD;
        -  pos. bacterial culture,&#xD;
&#xD;
        -  erythema&#xD;
&#xD;
             -  Urine culture if indicated by sediment (at withdrawl of bladder cathe-ter,&#xD;
                discolored urine or fever)&#xD;
&#xD;
             -  Blood culture (if fever above 39°C after POD2)&#xD;
&#xD;
             -  Tracheal secretion (if expectoration is prutride or radiological indica-tion of&#xD;
                bronchopneumonia)&#xD;
&#xD;
             -  Antibiotic treatment, duration, amounts, multidrug use&#xD;
&#xD;
      Woundhealing and the occurrence of infections were classified with the ASEPSIS score: Of&#xD;
      influence is the duration of antibiotic treatment, drainage of pus, wound de-bridements,&#xD;
      erythema, involvement of deeper tissue layers, identification of bacteria, LOS above 14 days&#xD;
      17.&#xD;
&#xD;
      Infection Definition&#xD;
&#xD;
      Occurrence of any infection is defined as&#xD;
&#xD;
        -  Elevation of patient's temperature/fever above 38°C on POD 3 or later or&#xD;
&#xD;
        -  Leukocytosis above the cut off point (generated for every individual subject )or&#xD;
&#xD;
        -  BSG / CRP above the cut off point (generated for every individual subject ) or&#xD;
&#xD;
        -  Isolation of bacteria from any fluid including pus or&#xD;
&#xD;
        -  Abscess (verificated by surgical drainage or ultrasonographically guided aspiration of&#xD;
           pus ) or&#xD;
&#xD;
        -  Arthritis by local clinical symptoms and surgical drainage&#xD;
&#xD;
      Wound infection is assessed by the ASEPSIS score&#xD;
&#xD;
      Urinary tract infection is defined as&#xD;
&#xD;
        -  new isolated occurrence of leukocytosis, and/or nitrite, and/or protein or&#xD;
&#xD;
        -  isolation of bacteria more than 10 000/µl (sediment) or&#xD;
&#xD;
        -  growth of more than 100 000 colonies of a single organism in the culture&#xD;
&#xD;
      Respiratory airway infection is defined as&#xD;
&#xD;
        -  positive x-ray (chest infiltrate) and fever or&#xD;
&#xD;
        -  dyspnea or cough or purulent sputum and fever or&#xD;
&#xD;
        -  isolation of bacteria in tracheal secretion (only intubated subjects) and fever&#xD;
&#xD;
      Septicemia is defined as&#xD;
&#xD;
      • clinical symptoms and positive blood culture&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood loss and transfusion rate</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1089</enrollment>
  <condition>Infection</condition>
  <condition>Bacterial Infection</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>storage and transfusion of autologous whole blood without leukocyte depletion : Control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>storage and transfusion of leukocyte depleted autologous whole blood : leukocyte depletion group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>leukocyte depletion of whole blood</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Leukocyte filtration/Depletion</intervention_name>
    <description>leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Fresenius leukocyte depletion whole blood filters</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • ASA I-III,&#xD;
&#xD;
               -  Age 18-85 years,&#xD;
&#xD;
               -  Body weight 50-125 kg&#xD;
&#xD;
               -  If female, with either a history of an accepted method of anticonception for at&#xD;
                  least 3 month prior and 1 month following the termination of the study or&#xD;
                  climacteric or with a negative betA- HCG-Test in urine or serum.&#xD;
&#xD;
               -  Preoperative blood donation of at least 2 units (450mL whole blood)&#xD;
&#xD;
               -  Preoperative hemoglobin level &gt; 10 mg/dL&#xD;
&#xD;
               -  Able and willing to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a contraindication for preoperative blood donation (PAD) (in 12, PP&#xD;
             36-43).&#xD;
&#xD;
               -  systemic infection&#xD;
&#xD;
               -  acute bacterial or viral diseases&#xD;
&#xD;
               -  anemia (Hb &gt; 11g/dL)&#xD;
&#xD;
               -  myocardial infarction within the past 6 month,&#xD;
&#xD;
               -  instable angina pectoris&#xD;
&#xD;
               -  vascular stenosis (i.e. of the coronary or internal carotid arteries)&#xD;
&#xD;
               -  hemodynamic relevant valvular stenosis&#xD;
&#xD;
               -  heart failure &gt; NYHA II&#xD;
&#xD;
               -  history of strokes or TIA&#xD;
&#xD;
               -  steroid therapy,&#xD;
&#xD;
               -  immune deficiency,&#xD;
&#xD;
               -  hematological or endocrinological disease,&#xD;
&#xD;
               -  coagulopathy,&#xD;
&#xD;
               -  history of organ transplantation,&#xD;
&#xD;
               -  simultaneous participation in a second study&#xD;
&#xD;
               -  pregnancy&#xD;
&#xD;
               -  membership at Jehovah's Witnesses&#xD;
&#xD;
               -  intended use of a cell saver&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Frietsch, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinic of Anesthesiology and Critical Care Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic of Anesthesiology and Critical Care Medicine, Faculty of Clinical Medicine MAnnheim, University of Heidelberg, Germany</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Garmisch Partenkirchen</name>
      <address>
        <city>Garmisch Partenkirchen</city>
        <state>Bavaria</state>
        <zip>82467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Transfusion Medicine and Hemostasiology, University of MArburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Byrne DJ, Malek MM, Davey PG, Cuschieri A. Postoperative wound scoring. Biomed Pharmacother. 1989;43(9):669-73.</citation>
    <PMID>2696565</PMID>
  </reference>
  <reference>
    <citation>Frietsch T, Fessler H, Kirschfink M, Nebe T, Waschke KF, Lorentz A. Immune response to autologous transfusion in healthy volunteers: WB versus packed RBCs and FFP. Transfusion. 2001 Apr;41(4):470-6. Erratum in: Transfusion 2001 Jun;41(6):851.</citation>
    <PMID>11316896</PMID>
  </reference>
  <reference>
    <citation>Frietsch T, Krombholz K, Tolksdorf B, Nebe T, Segiet W, Lorentz A. Cellular immune response to autologous blood transfusion in hip arthroplasty: whole blood versus buffy coat-poor packed red cells and fresh-frozen plasma. Vox Sang. 2001 Oct;81(3):187-93.</citation>
    <PMID>11703863</PMID>
  </reference>
  <reference>
    <citation>Lorentz A, Osswald PM, Schilling M, Jani L. [A comparison of autologous transfusion procedures in hip surgery]. Anaesthesist. 1991 Apr;40(4):205-13. German.</citation>
    <PMID>2058822</PMID>
  </reference>
  <reference>
    <citation>Tolksdorf B, Frietsch T, Quintel M, Kirschfink M, Becker P, Lorentz A. Humoral immune response to autologous blood transfusion in hip surgery: whole blood versus packed red cells and plasma. Vox Sang. 2001 Oct;81(3):180-6.</citation>
    <PMID>11703862</PMID>
  </reference>
  <reference>
    <citation>Frietsch T, Lorentz A. Predonation of autologous blood is jeopardized by new regulations. Eur J Anaesthesiol. 2001 Oct;18(10):629-31.</citation>
    <PMID>11553239</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>June 9, 2008</last_update_submitted>
  <last_update_submitted_qc>June 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Thomas Frietsch, MD PhD</name_title>
    <organization>University of Heidelberg</organization>
  </responsible_party>
  <keyword>leukocyte depletion, autologous transfusion,</keyword>
  <keyword>infection</keyword>
  <keyword>bacterial infection</keyword>
  <keyword>sepsis, antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

